このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Slow Multiallergen Oral Immunotherapy in Young Children (InFO)

2026年10月23日 更新者:Idun Holmdahl、Karolinska Institutet

乳児食物アレルゲン経口免疫療法 (InFO)

The aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose against food allergy in young children (0.5-3 years) is safe and effective, a method to cure food allergy and to prevent the development of new food allergies.

Clinical randomized controlled (1:1) blinded interventional trial (RCT) with 2 intervention arms (group A and B).

Among 80 children reacting at the multiallergen food challenge, 40 children will be randomized to receive OIT (oral immunotherapy) with multiallergen powder with a final dose of approximately 200 mg protein of each included food (egg, milk, soy, wheat, walnut, peanut, hazelnut, cashew, almond, lentils)(group A) or to receive placebo powder (gluten-free oatmeal) (group B).

A sub-analysis will be performed of the children not reacting to the baseline challenge, who will be randomized to eat a low dose of the multiallergen powder (group C) or placebo powder (gluten-free oatmeal) (group D) and no specific advice.

調査の概要

詳細な説明

Today, there is no established curative treatment for food allergies, and those affected must avoid the food that triggers symptoms. The most studied method is oral immunotherapy (OIT) which have mainly been carried out on children >4 years of age. The OIT method implies that the allergic individual eats initially very low doses and gradually increasing amounts of the allergen until a maintenance dose is reached. The treatment aims to induce desensitization or tolerance to the allergen.

Intervention: The intervention substance is a powder containing a prespecified amount of 10 allergens (egg, milk, wheat, lentils, soy, walnut, peanut, hazelnut, cashew, almond), which are the most triggering allergens in children. The product is developed in cooperation with Research Institute of Sweden (RISE).

Clinical randomized controlled (1:1) blinded interventional trial (RCT) with 2 interventions arms (group A and B). A sub-analysis will be performed of the children not reacting to the baseline challenge (group C and D).

Group A: Children with food allergy (sensitization and positive baseline challenge), receiving multiallergen powder OIT, slow up-dosing until 3 teaspoons of the multiallergen powder is reached daily. Food challenge will be performed after 1 and 2 years. 2 years treatment.

Group B: Children with food allergy (sensitization and positive baseline challenge), receiving OIT with placebo (gluten-free oatmeal) followed by maintenance, in total 2 years. Food challenge will be performed after 1 and 2 years.

After the first 20 participants in groups A and B have completed the one-year challenge, tolerance will be evaluated. If children in group A have a statistically significant (p < 0.05) higher tolerated cumulative dose at the one-year challenge than group B the multiallergen powder is considered more effective than placebo and all children in group B will be offered a cross-over following the one-year challenge.

Group C and D: sensitized children with a negative baseline challenge will be randomized 1:1 for treatment with multiallergen powder or placebo powder in a lower amount, 1 teaspoon daily and can introduce food in accordance with Swedish guidelines. After one year a food challenge will be performed.

Selection for group A to D: All children 0.5-3 years of age in Stockholm County who had a positive blood test for suspected food allergy to one or more of the 10 included allergens with specific immunoglobulin E (IgE) >0.1 kUA/L, are eligible as possible study participants. The data is obtained from the Karolinska University Laboratory's test results register. Information letters will be sent to families with IgE-sensitized children.

Inclusion groups A to D: Children 0.5-3 years old at inclusion with positive IgE >0.1 kUA/L against at least one of the 10 above mentioned allergens. Eighty children, group A (n=40) and group B (n=40) also need a positive baseline food challenge.

Children with a negative food challenge (group C and D) (number is not determined) do not react at the baseline challenge.

Primary outcome: Tolerance to 900 mg protein, cumulative dose, of each of the 10 included allergens, at the food challenge after two years OIT treatment or placebo (group A and B).

Secondary outcomes: Tolerance to cumulative dose of 900 mg protein of each food, evaluated with a food challenge after one years in all children (group A-D). Changes in immunological markers, eczema and asthma status and changes in quality of life in relation to interventions.

研究の種類

介入

入学 (推定)

80

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6ヶ月~3年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 0.5-3 years old at inclusion with IgE (>0.1 kUA/l) against at least one allergen (wheat, lentils, egg, milk, soy, walnut, hazelnut, peanut, almond, cashew).
  • Written consent for participation in the study for both guardians.
  • 80 children (group A and B) also need a positive baseline food challenge.
  • Children with a negative food challenge (group C and D) (number not determined) do not react at the baseline challenge.

Exclusion Criteria:

  • other serious illness
  • previous life-threatening anaphylaxis (intensive care)
  • eosinophilic esophagitis
  • eosinophilic gastrointestinal disease
  • severe chronic gastroesophageal reflux disease
  • unclear recurrent GI complaints
  • low body weight <2SD
  • participation in another intervention study if included in intervention group
  • severe uncontrolled asthma
  • medication with biological drugs or oral steroids.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Group A: Allergic children - Multiallergen OIT

Children with food allergy receiving multiallergen powder OIT. Multiallergen food challenge is done before randomization and one and two years after inclusion. OIT multiallergen powder with slow up-dosing until 3 teaspoons of the multiallergen powder is reached and taken daily. 2 years treatment.

Number = 40 patients

Intervention: multiallergen powder

OIT multiallergen powder.

介入なし:Group B: Allergic children - Placebo powder

Children with food allergy receiving OIT with placebo powder (gluten-free oatmeal). Multiallergen food challenge is done before randomization and one and two years after inclusion.

Number = 40 patients

アクティブコンパレータ:Group C: Non-allergic children - low dose multiallergen powder

Children not reacting to the baseline challenge who will be randomized to eat a low dose of the multiallergen powder, 1 teaspoon daily. Multiallergen food challenge is done before randomization and one year after inclusion. 1 year treatment.

Number = X

Intervention: Multiallergen powder

OIT multiallergen powder.

介入なし:Group D: Non-allergic children - placebo powder

Children not reacting to the baseline challenge who will be randomized to eat placebo powder (gluten-free oatmeal) and no specific advice.

Number= X

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Tolerance to 900 mg protein at a food challenge after 2 years
時間枠:2 years

Tolerance to 900 mg protein, cumulative dose, of each of the 10 included allergens (in the multiallergen powder), evaluated at a food challenge after 2 years in group A and B. Tolerance is defined as no objective sign of an allergic symptom (urticaria, flush, swelling/angioedema, nasal symptoms, eye symptoms, hoarseness, muffled speech, persistent cough, wheezing, stridor, persistent abdominal pain, severe nausea, vomiting, diarrhea, general impact, drop in blood pressure, decreased oxygenation saturation) within 2 hours after the last dose during the food challenge after 2 years of OIT/placebo.

2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Tolerance to cumulative dose of 900 mg protein at a food challenge after 1 year
時間枠:1 year

Tolerance to cumulative dose of 900 mg protein of each of the 10 included allergens in the multiallergen powder, evaluated at a food challenge after one year in all children (A, B, C, D).

Tolerance is defined as no objective sign of an allergic symptom (urticaria, flush, swelling/angioedema, nasal symptoms, eye symptoms, hoarseness, muffled speech, persistent cough, wheezing, stridor, persistent abdominal pain, severe nausea, vomiting, diarrhea, general impact, drop in blood pressure, decreased oxygenation saturation) within 2 hours after the last dose during the food challenge after one year.

1 year
Oral brush samples
時間枠:1 and 2 years

The oral microbiome will be investigated with sequencing-based methods to monitor possible changes in the oral microbiota composition and function related to OIT treatment. Comparisons will be made between intervention groups and analyzed in relation to intervention. Oral brush samples will be collected in connection with the visit for the baseline challenge, at the challenge at 1 years (group A-D) and 2 years (group A-B).

1 and 2 years
Intestinal microbiome
時間枠:1 and 2 years

The gut microbiome will be investigated with sequencing-based methods to monitor possible changes in the gut microbiota composition and function related to OIT treatment. Comparisons will be made between intervention groups and analyzed in relation to intervention. Fecal samples will be collected in connection with the visit for the baseline challenge, at the challenge at 1 years (group A-D) and 2 years (group A-B).

1 and 2 years
Immunological biomarkers
時間枠:1 and 2 years

To study different immunological biomarkers (e.g. T-helper cell population and polarization and IgE-levels) before, during and after OIT treatment and compare this to the placebo group. Immunological marker in mononuclear cells in peripheral blood will be analyzed ex vivo with flowcytometri and RNA-sequencing platforms. Circulating immunological factors, e.g. cytokines and chemokines will be analyzed in plasma with ELISA-based methods. Mononuclear cellpopulations in peripheral blood will be exposed to different stimuli (such as sensitizing allergen, anti-C D3/ C D28) in vitro, type and level of reaction in the different cellpopulations will be monitored at mRNA- and protein-level.

Blood sampling will be collected in connection with the visit for the baseline challenge, at the challenge at 1 years (group A-D) and 2 years (A-B).

1 and 2 years
Changes in eczema status in relation to interventions
時間枠:1 and 2 years

Clinical examination including eczema grading will be performed at the food challenges and basic clinical examination at each study-visit. Eczema grading will be evaluated using Eczema area and severity index (EASI), score between 0-72.

1 and 2 years
Changes in asthma status in relation to interventions
時間枠:1 and 2 years

Clinical examination including evaluation asthma status will be performed at the food challenges and basic clinical examination at each study-visit. Asthma status will be evaluated with a clinical examination, use of asthma medication, number of wheezing episodes as well as hospitalization prior to the study visit.

1 and 2 years
Changes in quality of life in relation to interventions
時間枠:1 and 2 years

To evaluate changes in quality of life before and after multiallergen OIT using the "Food allergy quality of life questionnaire-parental form" (FAQLQ-PF) validated and translated into Swedish. Comparisons will be made between the OIT group and the placebo group. FAQLQ-PF is a multidimensional parent report measure to assess children between 0-12 years. There are 14 items for children below 4 years old which are scored on a 7 point scale from 0 (no impact of HRQL) to 6 (extreme impact of HRQL). FAQLQ-PF include questions for food-allergy specific QoL with general emotional impact, food anxiety, social and dietary limitations. Overall and domain specific HRQL scores will be calculated. Higher score mean worse outcome and a score of ≥ ±0.5 will be considered clinically relevant.

1 and 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Caroline Nilsson, MD, PhD、Karolinska Institutet
  • 主任研究者:Anna Asarnoj, MD, PhD、Karolinska Institutet

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年11月8日

一次修了 (推定)

2027年9月1日

研究の完了 (推定)

2029年12月1日

試験登録日

最初に提出

2024年7月12日

QC基準を満たした最初の提出物

2024年7月29日

最初の投稿 (実際)

2024年8月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月27日

QC基準を満たした最後の更新が送信されました

2026年10月23日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Dnr 2024-03574-02

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する